Oxytocin treatment for core symptoms in children with autism spectrum disorder: a systematic review and meta-analysis
- PMID: 37540265
- DOI: 10.1007/s00228-023-03545-w
Oxytocin treatment for core symptoms in children with autism spectrum disorder: a systematic review and meta-analysis
Abstract
Purpose: The purpose of this article is to examine the efficacy of oxytocin in treating core symptoms of autism spectrum disorder (ASD) with children.
Methods: A systematic literature search was conducted to identify randomized controlled trials (RCTs) of oxytocin for the treatment of core symptoms in children with ASD. The search included studies published between January 1, 1999 and March 15, 2023, that were randomized, single or double-blinded, and included a placebo control group. Standard screening rules were applied to select relevant studies, resulting in the inclusion of five RCTs involving 486 children with ASD.
Results: Ultimately, a total of five RCTs, involving 486 children with ASD, were included in the review using standard screening rules.One of the included studies demonstrated a statistically significant improvement in Social Responsiveness Scale (SRS) and Repetitive Behavior Scale-Revised (RBS) scores when children with ASD were treated with oxytocin (24 IU/2 days for 6 weeks). The improvement in core symptoms persisted at the 6-month follow-up. The meta-analysis findings suggested that oxytocin might have a moderate effect in improving the core symptom of narrow interests and repetitive stereotyped behaviors in children with ASD.
Conclusion: While the therapeutic value of oxytocin in treating core symptoms of ASD in children is not fully established, the results of this meta-analysis indicate a potential moderate effect. However, further studies with larger sample sizes and more robust RCTs are needed to directly demonstrate the efficacy of oxytocin. Future research should also focus on effect size and outcome evaluation accuracy while minimizing bias in RCT experiments.
Keywords: Children autism spectrum disorder; Meta-analysis; Oxytocin; Systematic review.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders: meta-analysis and dose-response meta-analysis of randomized controlled trials.Front Psychiatry. 2025 Jan 29;15:1477076. doi: 10.3389/fpsyt.2024.1477076. eCollection 2024. Front Psychiatry. 2025. PMID: 39944132 Free PMC article.
-
Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial.Mol Autism. 2023 Apr 20;14(1):16. doi: 10.1186/s13229-023-00546-5. Mol Autism. 2023. PMID: 37081454 Free PMC article. Clinical Trial.
-
Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis.Neurosci Biobehav Rev. 2021 Mar;122:18-27. doi: 10.1016/j.neubiorev.2020.12.028. Epub 2021 Jan 2. Neurosci Biobehav Rev. 2021. PMID: 33400920
-
[The Possible Role of Oxytocin in Autism Spectrum Disorder].Seishin Shinkeigaku Zasshi. 2016;118(6):399-409. Seishin Shinkeigaku Zasshi. 2016. PMID: 30620499 Japanese.
-
The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.Cochrane Database Syst Rev. 2021 Feb 14;2(2):CD013457. doi: 10.1002/14651858.CD013457.pub2. Cochrane Database Syst Rev. 2021. PMID: 33583058 Free PMC article.
Cited by
-
Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders: meta-analysis and dose-response meta-analysis of randomized controlled trials.Front Psychiatry. 2025 Jan 29;15:1477076. doi: 10.3389/fpsyt.2024.1477076. eCollection 2024. Front Psychiatry. 2025. PMID: 39944132 Free PMC article.
-
The Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease.Endocr Rev. 2025 Jul 15;46(4):518-548. doi: 10.1210/endrev/bnaf008. Endocr Rev. 2025. PMID: 39985439 Free PMC article. Review.
-
Behavioural disorders and sleep problems in Sanfilippo syndrome: overlaps with some other conditions and importance indications.Eur Child Adolesc Psychiatry. 2025 Jun;34(6):1795-1816. doi: 10.1007/s00787-025-02661-5. Epub 2025 Mar 15. Eur Child Adolesc Psychiatry. 2025. PMID: 40087177 Review.
-
Vasopressin as Possible Treatment Option in Autism Spectrum Disorder.Biomedicines. 2023 Sep 22;11(10):2603. doi: 10.3390/biomedicines11102603. Biomedicines. 2023. PMID: 37892977 Free PMC article. Review.
References
-
- Amaral DG, Anderson MP, Ansorge O et al (2018) Autism BrainNet: a network of postmortem brain banks established to facilitate autism research. Handb Clin Neurol.15031–9. https://doi.org/10.1016/b978-0-444-63639-3.00003-7 .
-
- Maenner MJ, Shaw KA, Baio J et al (2020) Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2016. MMWR Surveill Summ 69(4):1–12. https://doi.org/10.15585/mmwr.ss6904a1 .
-
- Maenner MJ, Shaw KA, Bakian AV et al (2021) Prevalence and characteristics of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2018. MMWR Surveill Summ 70(11):1–16. https://doi.org/10.15585/mmwr.ss7011a1 .
-
- Lord C, Charman T, Havdahl A et al (2022) The Lancet Commission on the future of care and clinical research in autism. Lancet 399(10321):271–334. https://doi.org/10.1016/s0140-6736(21)01541-5 - DOI - PubMed
-
- Hirota T, King BH (2023) Autism spectrum disorder: a review Jama 329(2):157–168. https://doi.org/10.1001/jama.2022.23661 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical